Location History:
- Praha, CZ (2012)
- Prague, CZ (2007 - 2015)
Company Filing History:
Years Active: 2007-2015
Title: The Innovative Contributions of Ludek Ridvan
Introduction
Ludek Ridvan is a notable inventor based in Prague, Czech Republic, recognized for his substantial contributions to pharmaceutical science. With a portfolio of seven patents, his work primarily revolves around the development of novel pharmaceutical compounds and methods.
Latest Patents
Ridvan's most recent inventions include two significant patents that showcase his expertise in pharmaceutical formulations. The first patent, titled "Pharmaceutically acceptable cocrystals of N-[2-(7-methoxyl-1-naphtyl)ethyl]acetamide and methods of their preparation," presents novel solid forms of agomelatine. This invention highlights the methods for preparing these cocrystals, which exhibit physicochemical properties suitable for pharmaceutical development.
His second patent focuses on "Salts of desvenlafaxine and a method of their preparation." This invention involves new salts of the desvenlafaxine base, specifically the hydrogen oxalate and hemioxalate, which demonstrate innovative approaches to creating effective pharmaceutical compounds.
Career Highlights
Throughout his career, Ludek Ridvan has made significant strides in the pharmaceutical industry. He has contributed his expertise and innovative thinking while working with notable organizations, including Zentiva and the University of California. His role in these institutions has been pivotal in advancing pharmaceutical research and development.
Collaborations
Ridvan has collaborated with distinguished colleagues, including Tomas Pekarek and Monika Zatopkova. These partnerships have allowed him to explore diverse avenues of research, leading to breakthroughs in pharmaceutical formulations and enhancing their efficacy.
Conclusion
Ludek Ridvan's commitment to innovation in the pharmaceutical field is evident through his extensive patent portfolio and collaborative work. His inventions not only contribute to advancements in drug development but also reflect his dedication to improving patient care through innovative pharmaceutical solutions.